Liver injury related to vascular endothelial growth factor tyrosine kinase inhibitors: a pharmacovigilance analysis of the USA FDA adverse event reporting system (FAERS) database
Authors:
- 4 February 2025
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- p. 1-9
Abstract
BackgroundWhile vascular endothelial growth factor tyrosine kinase inhibitors (VEGFR-TKIs) are known to cause adverse events like cardiotoxicity and haematotoxicity, their impact on liver injury remains understudied. This study evaluates the association between VEGFR-TKIs and liver injury using data from the FDA Adverse Event Reporting System (FAERS) database from 2006 to 2024.Research design and methodsNine VEGFR-TKIs (Axitinib, Vandetanib, Cabozantinib, Lenvatinib, Pazopanib, Ponatinib, Regorafenib, Sunitinib, Sorafenib) were analyzed. Disproportionality and Bayesian analyses identified cases of VEGFR-TKI-induced liver injury, assessing onset time, mortality, and hospitalization rates.Results8,619 cases of liver injury were identified. Pazopanib had the highest association with liver injury (reporting odds ratio 3.9). The median onset of liver injury was 21 days. Mortality was 28.5%, with Sorafenib linked to the highest mortality (48.6%). Lenvatinib had the highest hospitalization rate (56%).ConclusionVEGFR-TKIs are associated with liver injury. Close monitoring is required to mitigate the risks of hospitalization and early mortality during treatment.Keywords
Funding Information
- National Natural Science Foundation of China (No. 82000388)
- Natural Science Foundation of Hunan Province (2020JJ4900)
This publication has 63 references indexed in Scilit:
- Liver stiffness in magnetic resonance elastography is prognostic for sorafenib-treated advanced hepatocellular carcinomaEuropean Radiology, 2020
- Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug‐drug interactions and hepatotoxicityMedicinal Research Reviews, 2019
- Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERSClinical Drug Investigation, 2019
- Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysisCancer Medicine, 2018
- Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized DosingClinical Pharmacokinetics, 2017
- Effects of 31 FDA approved small-molecule kinase inhibitors on isolated rat liver mitochondriaArchives of Toxicology, 2016
- Clinical Pharmacokinetics and Pharmacodynamics of CabozantinibClinical Pharmacokinetics, 2016
- Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumorsCancer Chemotherapy and Pharmacology, 2013
- High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injuryHepatology, 2012
- Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinomaHepatology International, 2011